http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 16:17:33 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/NeoGenomics+wins+Medicare+coverage+for+cancer+immunotherapy+test/26982035.html <p>NeoGenomics, Inc. (NASDAQ: NEO) announced that its RaDaR ST molecular residual disease (MRD) assay has received expanded Medicare coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program to include immunotherapy response monitoring in patients with late-stage solid tumors.</p><p>This marks the third Medicare-covered indication for RaDaR ST. The test was previously covered for HPV-negative head and neck squamous cell carcinoma and a subset of hormone receptor-positive, HER2-negative breast cancer. NeoGenomics said it has two additional RaDaR ST submissions pending with the program.</p><p>The new coverage applies to monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage http://www.streetinsider.com/Corporate+News/NeoGenomics+wins+Medicare+coverage+for+cancer+immunotherapy+test/26982035.html Wed, 26 Aug 2026 16:17:33 -0400 NEO http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html <p class="bwalignc"> <i>New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum</i> </p> <p> FORT MYERS, Fla.--(BUSINESS WIRE)-- <b>NeoGenomics, Inc. (NASDAQ: NEO)</b>, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors. </p><p> Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html Wed, 26 Aug 2026 16:17:00 -0400 A.28005717 NEO O.01687242 O.20020231 http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html <p class="bwalignc"> <i>New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum</i> </p> <p> FORT MYERS, Fla.--(BUSINESS WIRE)-- <b>NeoGenomics, Inc. (NASDAQ: NEO)</b>, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors. </p><p> Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html Wed, 26 Aug 2026 16:17:00 -0400 A.28005717 NEO O.01687242 O.20020231 http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html <p class="bwalignc"> <i>New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum</i> </p> <p> FORT MYERS, Fla.--(BUSINESS WIRE)-- <b>NeoGenomics, Inc. (NASDAQ: NEO)</b>, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors. </p><p> Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html Wed, 26 Aug 2026 16:17:00 -0400 A.28005717 NEO O.01687242 O.20020231 http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html <p class="bwalignc"> <i>New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum</i> </p> <p> FORT MYERS, Fla.--(BUSINESS WIRE)-- <b>NeoGenomics, Inc. (NASDAQ: NEO)</b>, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors. </p><p> Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html Wed, 26 Aug 2026 16:17:00 -0400 A.28005717 NEO O.01687242 O.20020231 http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html <p class="bwalignc"> <i>New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum</i> </p> <p> FORT MYERS, Fla.--(BUSINESS WIRE)-- <b>NeoGenomics, Inc. (NASDAQ: NEO)</b>, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors. </p><p> Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html Wed, 26 Aug 2026 16:17:00 -0400 A.28005717 NEO O.01687242 O.20020231 http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html <p class="bwalignc"> <i>New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum</i> </p> <p> FORT MYERS, Fla.--(BUSINESS WIRE)-- <b>NeoGenomics, Inc. (NASDAQ: NEO)</b>, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors. </p><p> Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html Wed, 26 Aug 2026 16:17:00 -0400 A.28005717 NEO O.01687242 O.20020231 http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html <p class="bwalignc"> <i>New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum</i> </p> <p> FORT MYERS, Fla.--(BUSINESS WIRE)-- <b>NeoGenomics, Inc. (NASDAQ: NEO)</b>, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors. </p><p> Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html Wed, 26 Aug 2026 16:17:00 -0400 A.28005717 NEO O.01687242 O.20020231 http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html <p class="bwalignc"> <i>New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum</i> </p> <p> FORT MYERS, Fla.--(BUSINESS WIRE)-- <b>NeoGenomics, Inc. (NASDAQ: NEO)</b>, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors. </p><p> Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html Wed, 26 Aug 2026 16:17:00 -0400 A.28005717 NEO O.01687242 O.20020231 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+21++Filed+by%3A+Stone+Warren/26975213.html si-local-file:///var/storage/secattach/20260825/26975213.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+21++Filed+by%3A+Stone+Warren/26975213.html Tue, 25 Aug 2026 16:33:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+21++Filed+by%3A+Stone+Warren/26975213.html si-local-file:///var/storage/secattach/20260825/26975213.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+21++Filed+by%3A+Stone+Warren/26975213.html Tue, 25 Aug 2026 16:33:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NEOGENOMICS+INC++++++++++++++++++++++/26974593.html si-local-file:///var/storage/secattach/20260825/26974593.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NEOGENOMICS+INC++++++++++++++++++++++/26974593.html Tue, 25 Aug 2026 16:02:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NEOGENOMICS+INC++++++++++++++++++++++/26974593.html si-local-file:///var/storage/secattach/20260825/26974593.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NEOGENOMICS+INC++++++++++++++++++++++/26974593.html Tue, 25 Aug 2026 16:02:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26931955.html si-local-file:///var/storage/secattach/20260814/26931955.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26931955.html Fri, 14 Aug 2026 16:42:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26931955.html si-local-file:///var/storage/secattach/20260814/26931955.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26931955.html Fri, 14 Aug 2026 16:42:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+07/26905791.html si-local-file:///var/storage/secattach/20260811/26905791.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+07/26905791.html Tue, 11 Aug 2026 16:10:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+07/26905791.html si-local-file:///var/storage/secattach/20260811/26905791.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+07/26905791.html Tue, 11 Aug 2026 16:10:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+04++Filed+by%3A+Aunan+Greg+D/26883344.html si-local-file:///var/storage/secattach/20260806/26883344.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+04++Filed+by%3A+Aunan+Greg+D/26883344.html Thu, 06 Aug 2026 16:02:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+04++Filed+by%3A+Aunan+Greg+D/26883344.html si-local-file:///var/storage/secattach/20260806/26883344.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+04++Filed+by%3A+Aunan+Greg+D/26883344.html Thu, 06 Aug 2026 16:02:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++144++++++++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+Aunan+Greg+D/26866762.html si-local-file:///var/storage/secattach/20260804/26866762.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+Aunan+Greg+D/26866762.html Tue, 04 Aug 2026 16:20:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++144++++++++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+Aunan+Greg+D/26866762.html si-local-file:///var/storage/secattach/20260804/26866762.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+Aunan+Greg+D/26866762.html Tue, 04 Aug 2026 16:20:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++144++++++++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+Sherman+Jeffrey+Scott/26843518.html si-local-file:///var/storage/secattach/20260730/26843518.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+Sherman+Jeffrey+Scott/26843518.html Thu, 30 Jul 2026 16:05:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++144++++++++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+Sherman+Jeffrey+Scott/26843518.html si-local-file:///var/storage/secattach/20260730/26843518.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+Sherman+Jeffrey+Scott/26843518.html Thu, 30 Jul 2026 16:05:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26842302.html si-local-file:///var/storage/secattach/20260730/26842302.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26842302.html Thu, 30 Jul 2026 13:32:00 -0400 NEO O.01687242 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26842302.html si-local-file:///var/storage/secattach/20260730/26842302.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NEOGENOMICS+INC++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26842302.html Thu, 30 Jul 2026 13:32:00 -0400 NEO O.01687242